Atai Life Sciences climbs on $390 mln Beckley Psytech merger deal

AtaiBeckley

02/06/2025 11:30

** U.S.-listed shares of Atai Life Sciences 9VC.DE, ATAI.O rise 10.4% to $2.55 premarket

** ATAI and Oxford-based Beckley Psytech announced plans to combine in an all-share transaction, creating a firm focused on psychedelic mental health therapies

** The deal values Beckley at about $390 mln

** The combined firm will operate under the name "atai Beckley" with a joint leadership team, cos say

** Beckley shareholders will receive about 105 mln new atai shares, representing roughly 31% of the combined firm, cos say

** A concurrent $30 mln private placement by Ferring Ventures and Adage Capital Partners will provide additional funding

** Deal expected to close in H2 of 2025

** As of last close, ATAI up 73.7% YTD

(Reporting by Kamal Choudhury in Bengaluru)

((Kamal.Choudhury@thomsonreuters.com;))